Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Update

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the recipient of a significant decline in short interest in June. As of June 30th, there was short interest totaling 116,653 shares, a decline of 46.4% from the June 15th total of 217,647 shares. Based on an average trading volume of 52,848 shares, the days-to-cover ratio is presently 2.2 days. Approximately 0.7% of the shares of the stock are short sold.

Marker Therapeutics Trading Down 1.4%

Shares of NASDAQ:MRKR opened at $1.44 on Wednesday. Marker Therapeutics has a 1 year low of $0.81 and a 1 year high of $4.07. The business has a fifty day simple moving average of $1.44 and a 200 day simple moving average of $1.52. The firm has a market cap of $24.00 million, a price-to-earnings ratio of -2.36 and a beta of 1.45.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. Marker Therapeutics had a negative return on equity of 73.29% and a negative net margin of 343.03%.The firm had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.78 million. On average, sell-side analysts forecast that Marker Therapeutics will post -1.17 EPS for the current year.

Institutional Trading of Marker Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC bought a new position in Marker Therapeutics in the 2nd quarter worth $33,000. Two Sigma Investments LP acquired a new position in shares of Marker Therapeutics during the 3rd quarter worth about $33,000. Virtu Financial LLC bought a new stake in Marker Therapeutics during the 3rd quarter valued at approximately $25,000. Boyer Financial Services Inc. acquired a new stake in Marker Therapeutics in the 4th quarter valued at approximately $57,000. Finally, Geode Capital Management LLC grew its holdings in Marker Therapeutics by 35.3% in the 4th quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock valued at $194,000 after buying an additional 34,028 shares during the last quarter. 22.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on MRKR. HC Wainwright reaffirmed a “buy” rating on shares of Marker Therapeutics in a report on Wednesday, May 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Marker Therapeutics in a research report on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Marker Therapeutics currently has a consensus rating of “Hold” and an average target price of $10.00.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.